Accueil
Mots-clés
Documents disponibles dans cette catégorie (17)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Périodique
S. C. SIGMON ; D. E. MOODY ; NUWAYSER E. S. ; G. E. BIGELOW | 2006Aim: Buprenorphine is an effective medication for treatment of opioid dependence. An injectable depot formulation of buprenorphine has been developed using biodegradable polymer microcapsule technology. This formulation may offer effective treat[...]
Périodique
G. K. HULSE ; D. E. ARNOLD-REED ; G. O'NEIL ; C. T. CHAN ; R. HANSSON ; P. O'NEIL | 2004The aim of this study was to profile and compare blood naltrexone and 6-ß-naltrexol levels with time following treatment with two sustained-release naltrexone preparations produced by GoMedical lndustries, Australia at a community heroin treatme[...]
Article : Périodique
Périodique
N. M. PETRY | 2004FRANÇAIS : Commentaire de l'article de Sigmon C et Al. publié dans ce numéro d'Addiction (1439-1449)
Article : Périodique
S. L. WALSH ; S. D. COMER ; M. R. LOFWALL ; B. VINCE ; N. LEVY-COOPERMAN ; D. KELSH ; M. A. COE ; J. D. JONES ; P. A. NUZZO ; F. TIBERG ; B. SHELDON ; S. KIM |Importance: Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations may be obviated by a sustained r[...]
Périodique
S. C. SIGMON ; C. J. WONG ; CHAUSMER A. L. ; I. A. LIEBSON ; G. E. BIGELOW | 2004FRANÇAIS : Chez15 usagers dépendant des opioïdes on a pratiqué soit un implant de buprénorphine 58 mg soit un placebo. La buprénorphine sous cutanée a supprimé les symptômes de sevrage et a eu des effets agonistes opioïdes. ENGLISH : Aims: Bu[...]
Périodique
J. E. CARRENO ; C. E. ALVAREZ ; G. I. SAN NARCISO ; M. T. BASCARAN ; DIAZ M. ; J. BOBES | 2003ENGLISH : A report is presented of treatment of 156 patients (male 98%) with opioid dependence (ICD-10 criteria) using a maintenance programme with depot opioid antagonists (naltrexone) as subcutaneous implants, started after an outpatient rap[...]
Article : Périodique
FRANÇAIS : La buprénorphine à libération prolongée, en dépôt sous-cutané, est une nouvelle option thérapeutique pour les personnes dépendantes aux opiacés. Entre octobre 2021 et décembre 2022, 42 usagers du CSAPA Bagneux ont pu bénéficier de ce[...]
Périodique
ENGLISH : Early relapse is common after opiate withdrawal and deprives addicts of important opportunities to develop new, opiate-free cognitive-behavioural habits. The oral opiate antagonist naltrexone (NTX) significantly reduces relapse only [...]
Article : Périodique
V. D. HOPE ; J. V. PARRY ; F. NCUBE ; M. HICKMAN |Background: The extent of intentional or accidental subcutaneous and intramuscular injections and the factors associated with these have rarely been studied among people who inject drugs, yet these may play an important role in the acquisition b[...]
Périodique
SOBEL B. F. X. ; S. C. SIGMON ; S. L. WALSH ; R. E. JOHNSON ; I. A. LIEBSON ; NUWAYSER E. S. ; KERRIGAN J. H. ; G. E. BIGELOW | 2004ENGLISH : Buprenorphine, a partial mu-opioid agonist, has been shown effective for treatment of opioid dependence but also has some abuse potential. A novel formulation of buprenorphine, using a polymer microcapsule depot sustained-release tec[...]
Rapport
United States Government Accountability Office | Washington, DC : U.S. Government Accountability Office (GAO) | 2020Treatment for opioid use disorder may involve buprenorphine - a drug that can reduce or eliminate withdrawal symptoms and prevent relapse. We reviewed the use of long-acting injectable and implantable forms of buprenorphine for opioid use disor[...]
Périodique
G. K. HULSE ; R. J. TAIT | 2003ENGLISH : Morbidity and mortality rates for regular heroin users are much greater than those observed in the general population. In `high-risk' heroin users implantable naltrexone has been used under Commonwealth Therapeutic Goods Administrati[...]
Périodique
CAMPISTOL J. M. ; MONTOLIU J. ; J. SOLER-AMIGO ; A. DARNELL ; REVERT L. | 1988
Périodique
E. L. MURPHY ; DE VITA D. ; H. LIU ; E. VITTINGHOFF ; P. LEUNG ; D. H. CICCARONE ; B. R. EDLIN | 2001ENGLISH : Skin and soft-tissue abscesses, a common problem among injection drug users (IDUs), result in serious morbidity for the patient and costly hospitalizations for incision and drainage, however, there has been little etiologic or preven[...]
